As a GLP-1 receptor agonist, retatrutide may carry similar risks to semaglutide , which include: Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All GLP-1 receptor agonists carry a boxed warning for thyroid tumors based on animal studies
These results are similar to those seen in mice that ectopically express the NPY gene and are also evident in mice that harbor a MC4R knock-out
Days 28-45: Gradual decline
Fortunately, Pure Med Spa Chicago ensures a steady supply of Semaglutide, so our patients never experience disruptions in their treatment
Thats one of the limitations of any database study. Overall, the findings add to growing evidence that GLP-1based therapies could offer benefits beyond glucose control in patients with Type 1 diabetes
Published Research Observations Scientific literature documents several consistent findings across BPC 157 studies